Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Not sure if LFDx is what we want to be. Its more sensitive at some lower viral loads/ higher Ct values but not others. Can Okehurst, Chiron or another expert add a perspective here?
Thanks Hundal
Anyone know how to buy the adr as a uk imvestor?
Normally you would expect a new test to be sold largely domestically and take up a few per cent of overall global market as a result. What changes that ia if a test is markedly best in class. Then the world becomes you oyster in terms of demand and attracting manufacturing capacity - easy to see a ramp to 20 per cent of global supply in this scenario.
I expect decent upticks on good performance figures alone - say 50p for BAMS and 150p for LFD. If we also get evidence of strong production capacity and good orders then I would say we will get 6 to 10 quid before they are even being used by patient. The valuation will stay relatively low compared to expected profits until the market can tangibly see how those profits are speeding up Avactas expansion in diagnostics and therapy. So whilst it might be well over a tenner by summer it will offer great risk reward even then alnd could end up 100 ex china in say 3 or 4 years once its oncology and other developments have a chance to fully mature
I would much appreciate if someone could tell me how I could bit the adr as a British citizen and what the tax implication s are
Your right comes up as Meningitis vaccine. Fantastic get that one too. Sometimes I ask for cafe latte and they give me caramel latte. So could easily end up giving you the mc vaccine when you wanted the AZ covid one.
We should get a 20 or25 k model 2 in a couple of years. Will sell like hotcakes